Early pregnancy loss encompasses biochemical pregnancy, embryonic demise, and missed abortion, each distinguished by specific hormonal profiles and ultrasound criteria within the NaProTECHNOLOGY surveillance model. CrMS-based cycle identification enables recognition of pregnancy at the earliest stages, allowing timely hormonal intervention when progesterone or estradiol deficits are detected.
how many pregnancies are lost before clinical recognition, is the 50 percent embryo loss claim accurate, Hertig Rock study problems and criticism, what is the real early miscarriage rate, Wilcox early pregnancy loss hCG study, chemical pregnancy how common and what causes it, is human reproduction naturally inefficient, early pregnancy loss rate cycle charting monitoring
Cite this article
Hilgers, T. W. (2004). Chapter 58: Early Pregnancy Loss. The Medical and Surgical Practice of NaProTECHNOLOGY, 797-801.
Hilgers TW. Chapter 58: Early Pregnancy Loss. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:797-801.
Hilgers, T. W. "Chapter 58: Early Pregnancy Loss." The Medical and Surgical Practice of NaProTECHNOLOGY, 2004, pp. 797-801.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
The CREIGHTON MODEL FertilityCare System (CrMS) rests on a decades-long body of research demonstrating that cervical mucus functions as a physiologically regulated biological valve, opening predictably at the periovulatory estrogen rise and closing in the post-Peak phase. Chapter 15 of Hilgers (2004) synthesizes hormonal, ultrasound, cytologic, and biophysical evidence to establish that a woman's external observation of her Peak Day reliably identifies the fertile window, and documents the system's effectiveness data for both achieving and avoiding pregnancy across a five-study meta-analysis of nearly 1,900 couples.
PCOSEpidemiology and PrevalenceMetabolic ReframeDefective Ovulatory Events
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
PCOS (polycystic ovary syndrome), increasingly designated PMOS (polycystic metabolic ovary syndrome) to reflect its metabolic complexity, is far more prevalent than its classic presentation suggests, affecting roughly six percent of reproductive-age women and carrying systemic consequences well beyond fertility disruption. This chapter from the foundational NaProTECHNOLOGY textbook maps the hormonal architecture of the condition, its ovulatory defect patterns, its frequent co-occurrence with endometriosis, and the restorative surgical and cycle-tracking approaches developed at the Pope Paul VI Institute.
Andrology/Male FactorCriteria and ClassificationMedical TreatmentSurgical Correction
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Male infertility plays a clinically significant role in a large share of couples who struggle to conceive, yet standard laboratory criteria for semen analysis were designed primarily to predict success with assisted reproduction, not natural fertility. NaProTECHNOLOGY approaches male factor as a diagnosable condition with identifiable root causes, applying medical and surgical options aimed at restoring sperm function and combining that work with fertility-awareness charting to maximize the couple's chances of natural conception.